<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395797</url>
  </required_header>
  <id_info>
    <org_study_id>6255</org_study_id>
    <secondary_id>R01DA031022</secondary_id>
    <nct_id>NCT01395797</nct_id>
  </id_info>
  <brief_title>Pioglitazone for Heroin and for Nicotine Dependence</brief_title>
  <official_title>Effects of Pioglitazone, a PPARγ Agonist, on the Abuse Liability of Heroin and of Nicotine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed research is to improve the effectiveness of treatments for opioid
      and for nicotine dependence by testing a novel pharmacological strategy. Specifically,
      pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be
      used as an adjunct to agonist-based treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although treatments for opioid and for nicotine dependence exist, these medications are not
      universally effective as many patients are unable to stop using or relapse rapidly,
      suggesting that treatment with a single agent alone is insufficient to facilitate cessation
      of use in many patients. Targeting additional pathways that may contribute to the
      maintenance of drug-taking behaviors or relapse may be a more effective strategy to treat
      individuals resistant to first-line approaches.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of drug choices</measure>
    <time_frame>Repeatedly during the 3-week study</time_frame>
    <description>Participants will be given the choice to self-administer drug (heroin or cigarettes) and the number of drug choices (range: 0-5) per day will be used as the primary outcome variable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective drug, mood, and physiological effects</measure>
    <time_frame>Repeatedly during the 3-weeks study</time_frame>
    <description>Visual analog scale ratings will be the primary endpoint (0-100 mm, 0=Not at all, 100=Extremely)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Heroin Dependence</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo - Heroin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control condition for active arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pio low dose - Heroin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose pio comparator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pio high dose - Heroin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose pio comparator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Nicotine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control condition for active arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pio Low Dose - Nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose pio comparator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pio High Dose - Nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose pio comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>0, 15, and 45 mg per day.</description>
    <arm_group_label>Pio low dose - Heroin</arm_group_label>
    <arm_group_label>Pio high dose - Heroin</arm_group_label>
    <arm_group_label>Placebo - Nicotine</arm_group_label>
    <arm_group_label>Pio Low Dose - Nicotine</arm_group_label>
    <arm_group_label>Pio High Dose - Nicotine</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - Heroin</description>
    <arm_group_label>Placebo - Heroin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-55 years of age

          -  Physically healthy

          -  Able to perform study procedures

        Exclusion Criteria:

          -  Pregnancy

          -  Physical dependence on any other drugs besides caffeine, heroin and nicotine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra D. Comer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>March 24, 2015</lastchanged_date>
  <firstreceived_date>July 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Heroin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
